Drug Trial Radar · NCT06914609
REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
156
Actual
Start
Jun 10, 2025
Primary completion
Aug 2027
Study completion Apr 2030
Sponsor
- Lead sponsor
- Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
- Sponsor type
- Industry
- First posted
- Apr 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of obudanersen in children and adults with Angelman syndrome caused by a deletion or mutation of the UBE3A gene.
Conditions
- Angelman Syndrome
Interventions
obudanersenDrug
obudanersen will be administered by IT injection.
PlaceboDrug
obudanersen matching placebo will be administered by IT injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Performance on the Expressive Communication Subdomain Raw Score of the Bayley Scales for Infant and Toddler Development-4 (Bayley-4) Without Caregiver Input in Cohort 1Time frame: Baseline and Week 52
Locations
39 sites in 12 countries. Site status is shown where the registry gives one.
Cedars-Sinai Medical Center
Los Angeles, California
UCLA Clinical & Translational Research Center (CTRC)
Los Angeles, California
Rady Children's Hospital
San Diego, California
Colorado Children's Hospital Research Institute
Aurora, Colorado
Children's National Hospital
Washington D.C., District of Columbia
Nicklaus Children's Hospital
Miami, Florida
Children's Healthcare of Atlanta
Atlanta, Georgia
Rush University Medical Center
Chicago, Illinois
Boston Children's Hospital
Boston, Massachusetts
Children's Mercy
Kansas City, Missouri
Ichan School of Medicine at Mount Sinai
New York, New York
University of North Carolina at Chapel Hill School of Medicine
Carrboro, North Carolina
Cincinnati Children's Hospital
Cincinnati, Ohio
Nationwide Children's Hospital
Columbus, Ohio
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Vanderbilt Clinical Research Center
Nashville, Tennessee
Texas Children's Hospital
Houston, Texas
Perth Children's Hospital
Nedlands, Australia
Sydney Children's Hospital
Randwick, Australia
Queensland Children's Hospital
South Brisbane, Queensland, Australia
University of Alberta Hospital
Edmonton, Canada
British Columbia Children's Hospital
Vancouver, Canada
London Health Science Centre - Children's Hospital
London, Ontario, Canada
McGill University Health Centre
Montreal, Quebec, Canada
Klinikum der Ludwig-Maximilians-Universitaet Muenchen
München, Germany
Sheba Medical Center
Ramat Gan, Israel
Fondazione IRCCS Istituto Neurologico Carlo Besta
Milan, Italy
Azienda Ospedaliero Universitaria Pisana
Pisa, Italy
Ospedale Pediatrico Bambino Gesù
Roma, Italy
Osaka Women's and Children's Hospital
Izumi, Osaka, Japan
National Center of Neurology and Psychiatry
Kodaira, Tokyo, Japan
Uniwersyteckie Centrum Kliniczne
Gdansk, Poland
KK Women's and Children's Hospital
Singapore, Singapore
Seoul National University Hospital
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Hospital Sant Joan de Deu
Barcelona, Spain
Corporacio Sanitaria Parc Tauli - Hospital de Sabadell
Sabadell, Spain
Great Ormond Street Hospital for Children - NHS Foundation Trust
London, United Kingdom
John Radcliffe Hospital
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.